Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with Low-Dose Intravitreal Triamcinolone Acetonide

Journal of Ocular Pharmacology and Therapeutics

Volumn 33, Issue 1, 2017, Pages 42-49

  Liang, I Chia ^a,b   Lin, Yi Ru ^a,c   Chien, Hsiang Wen ^a   Liu, Kwan Rong ^a,c,d  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

adjunctive therapy; polypoidal choroidal vasculopathy; triamcinolone acetonide

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRAIN ISCHEMIA; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; DRUG EFFICACY; FOLLOW UP; GLAUCOMA; HEART MUSCLE ISCHEMIA; HUMAN; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MALE; MIDDLE AGED; MONOTHERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PSEUDOPHAKIA; REPEATED DRUG DOSE; RETINA EDEMA; SUBRETINAL FLUID; VERY ELDERLY; VISUAL DISORDER; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85009516991     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0150     Document Type: Article

References (53)

1. Ciardella, A.P., Donsoff, I.M., Huang, S.J., Costa, D.L., and Yannuzzi, L.A. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 49:25-37, 2004.
2. Yannuzzi, L.A., Sorenson, J., Spaide, R.F., and Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 10:1-8, 1990.
3. Yuzawa, M., Mori, R., and Haruyama, M. A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 47:379-384, 2003.
4. Newman, D.K. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 30:202-210, 2016.
5. Akaza, E., Mori, R., and Yuzawa, M. Long-term results of photodynamic therapy of polypoidal choroidal vasculo-pathy. Retina. 28:717-722, 2008.
6. Gomi, F., Ohji, M., Sayanagi, K., et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 115:141-146, 2008.
7. Kurashige, Y., Otani, A., Sasahara, M., et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 146:513-519, 2008.
8. Sayanagi, K., Gomi, F., Sawa, M., Ohji, M., and Tano, Y. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 245:1569-1571, 2007.
9. Gomi, F., Sawa, M., Sakaguchi, H., et al. Efficacy of in-travitreal bevacizumab for polypoidal choroidal vasculo-pathy. Br J Ophthalmol. 92:70-73, 2008.
10. Koh, A., Lee, W.K., Chen, L.J., et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibi-zumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 32:1453-1464, 2012.
11. Koh, A.H., Chen, L.J., Chen, S.J., et al. Polypoidal cho-roidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 33:686-716, 2013.
12. Sato, T., Kishi, S., Matsumoto, H., and Mukai, R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 149:947-954.e941, 2010.
13. Ojima, Y., Tsujikawa, A., Otani, A., Hirami, Y., Aikawa, H., and Yoshimura, N. Recurrent bleeding after photody-namic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol. 141:958-960, 2006.
14. Hirami, Y., Tsujikawa, A., Otani, A., et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 27:335-341, 2007.
15. Sagong, M., Lim, S., and Chang, W. Reduced-fluence photodynamic therapy combined with intravitreal bev-acizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 153:873-882.e872, 2012.
16. Saito, M., Iida, T., and Kano, M. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina. 31:1589-1597, 2011.
17. Tolentino, M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 56:95-113, 2011.
18. Falavarjani, K.G., and Nguyen, Q.D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 27:787-794, 2013.
19. Martin, D.F., Maguire, M.G., Fine, S.L., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 119:1388-1398, 2012.
20. Chakravarthy, U., Harding, S.P., Rogers, C.A., et al. Alternative treatments to inhibit VEGF in age-related cho-roidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 382:1258-1267, 2013.
21. Wang, W., and Zhang, X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLoS One. 9:e109744, 2014.
22. Maguire, M.G., Martin, D.F., Ying, G.S., et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 123:1751-1761, 2016.
23. Cekic, O., Chang, S., Tseng, J.J., et al. Intravitreal triam-cinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 25:846-850, 2005.
24. Okubo, A., Ito, M., Kamisasanuki, T., and Sakamoto, T. Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 243: 837-839, 2005.
25. Kojima, A., Ohno-Matsui, K., Futagami, S., Shimada, N., Tokoro, T., and Mochizuki, M. Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascular-ization. Acta Ophthalmol Scand. 84:749-754, 2006.
26. Veritti, D., Sarao, V., and Lanzetta, P. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther. 29:437-441, 2013.
27. Selim, A., Kocak, N., Aslankara, H., and Kaynak, S. Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration. Turk J Med Sci. 44:889-895, 2014.
28. Yoshizawa, C., Saito, W., Hirose, S., Kitamei, H., Noda, K., and Ishida, S. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Jpn J Ophthalmol. 57:68-73, 2013.
29. Edelman, J.L., Lutz, D., and Castro, M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 80:249-258, 2005.
30. Zweifach, B.W., Shorr, E., and Black, M.M. The influence of the adrenal cortex on behavior of terminal vascular bed. Ann N Y Acad Sci. 56:626-633, 1953.
31. Jonas, J.B., Kreissig, I., Hugger, P., Sauder, G., Panda-Jonas, S., and Degenring, R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 87:462-468, 2003.
32. Uyama, M., Wada, M., Nagai, Y., et al. Polypoidal cho-roidal vasculopathy: natural history. Am J Ophthalmol. 133:639-648, 2002.
33. Spaide, R.F., Donsoff, I., Lam, D.L., et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 22:529-535, 2002.
34. Honda, S., Imai, H., Yamashiro, K., et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculo-pathy: a multicenter study in Hyogo preffecture, Japan. Ophthalmologica. 223:333-338, 2009.
35. Otani, A., Sasahara, M., Yodoi, Y., et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 144: 7-14, 2007.
36. Silva, R.M., Figueira, J., Cachulo, M.L., Duarte, L., Faria de Abreu, J.R., and Cunha-Vaz, J.G. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 243:973-979, 2005.
37. Ho, M., Lo, E.C., Young, A.L., and Liu, D.T. Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. Eye (Lond). 28: 1469-1476, 2014.
38. Saito, M., Iida, T., and Kano, M. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 32:1272-1279, 2012.
39. Imamura, Y., Engelbert, M., Iida, T., Freund, K.B., and Yannuzzi, L.A. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 55:501-515, 2010.
40. Nakashizuka, H., Mitsumata, M., Okisaka, S., et al. Clinicopathologic findings in polypoidal choroidal vas-culopathy. Invest Ophthalmol Vis Sci. 49:4729-4737, 2008.
41. Okubo, A., Sameshima, M., Uemura, A., Kanda, S., and Ohba, N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol. 86:1093-1098, 2002.
42. Fichte, C., Streeten, B.W., and Friedman, A.H. A histo-pathologic study of retinal arterial aneurysms. Am J Oph-thalmol. 85:509-518, 1978.
43. Ross, R.D., Gitter, K.A., Cohen, G., and Schomaker, K.S. Idiopathic polypoidal choroidal vasculopathy associated with retinal arterial macroaneurysm and hypertensive reti-nopathy. Retina. 16:105-111, 1996.
44. Freund, K.B., Zweifel, S.A., and Engelbert, M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 30:1333-1349, 2010.
45. Tong, J.P., Chan, W.M., Liu, D.T., et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculo-pathy and choroidal neovascularization. Am J Ophthalmol. 141:456-462, 2006.
46. Martidis, A., Miller, D.G., Ciulla, T.A., Danis, R.P., and Moorthy, R.S. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascu-larization. J Ocul Pharmacol Ther. 15:425-428, 1999.
47. Penfold, P.L., Wen, L., Madigan, M.C., King, N.J., and Provis, J.M. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 43:3125-3130, 2002.
48. Sarao, V., Veritti, D., Boscia, F., and Lanzetta, P. In-travitreal steroids for the treatment of retinal diseases. ScientificWorldJournal. 2014:989501, 2014.
49. Scott, I.U., Ip, M.S., VanVeldhuisen, P.C., et al. A randomized trial comparing the efficacy and safety of in-travitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 127:1115-1128, 2009.
50. Bakri, S.J., and Kaiser, P.K. Posterior subtenon triamcin-olone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 139:290-294, 2005.
51. Scott, I.U., and Flynn, H.W., Jr. Reducing the risk of en-dophthalmitis following intravitreal injections. Retina. 27:10-12, 2007.
52. Jonas, J.B., Kreissig, I., and Degenring, R.F. En-dophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol. 121:1663-1664, 2003.
53. Ip, M.S., Scott, I.U., VanVeldhuisen, P.C., et al. A randomized trial comparing the efficacy and safety of in-travitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 127:1101-1114, 2009.